InMed Pharmaceuticals, Inc. Stock Price - IMLFF

Best deals to access real time data!
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for OTC Markets and OTCBB
Monthly Subscription
for only
DDE w/Realtime (Monthly)
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type ISIN Company Description
Inmed Pharmaceuticals, Inc. (QB) IMLFF Other OTC Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  +0 +0% 0.546 - - - 0.546 08:01:26
Bid Price Ask Price Spread Spread % News
0.526 0.545 0.019 3.49% - -
Last Trade Time Type Quantity Stock Price Currency
- - - USD

Inmed Pharmaceuticals, Inc. (QB) Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 71.9M 131.69M $ -4.47M - -16.07 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Inmed Pharmaceuticals, Inc. (QB) News

Latest IMLFF Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical IMLFF Price Data

Period † Open High Low VWAP Min Vol Max Vol Avg. Daily Vol [m] Change %
1 Week0.5110.6750.49430.58001M4M2M0.0356.85%
1 Month0.31650.6750.2820.4773263k4M1M0.229572.51%
3 Months0.2320.6750.2050.4178107k4M755k0.314135.34%
6 Months0.4330.6750.1770.3672107k4M548k0.11326.10%
1 Year0.140.720.090.378338k5M716k0.406290.00%
3 Years0.1410.720.050.336205M288k0.405287.23%
5 Years0.01221.010.01220.337705M254k0.53384,375.41%

Inmed Pharmaceuticals, Inc. (QB) Description

InMed Pharmaceuticals Inc. is a pre-clinical stage biopharmaceutical company specializing in the research, development and commercialization of cannabinoid-based therapies to treat human diseases with high unmet medical needs. The Company has three core assets: a proprietary Bioinformatics assessment tool to match individual (or combination of) cannabinoids against disease targets; a proprietary Biosynthesis cannabinoid manufacturing system to economically produce all 90+ cannabinoids at pharmaceutical-grade (>99.5% purity); and drug development program enabled by the two aforementioned tools. Leaders in the pipeline include a treatment for the symptoms and, potentially, the underlying disease in Epidermolysis Bullosa, a rare, devastating genetic skin disorder; and, a once-a-day eyedrops formulation of cannabinoids to treat Glaucoma, one of the leading causes of blindness in the developed world.

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:43 V: D:20171120 13:30:16